Bookmark and Share

Last Minute:          For more news, click here.

Remember me? 

Show More News:
 Watch more news

News search related to the stock Celgene Corporati (ordered by date):

Healthcare Nanotechnology (Nanomedicine) Market Scope of ...  Digital Journal Marginal Zone Lymphoma Pipeline Appears Robust With 50+ Key ...  Digital Journal Stronger enforcement and sanctions for pharmaceutical infringements  Lexology Nanobiotechnology Market: Year 2023-2030 and its Detail Analysis ...  Digital Journal Increasing Opportunities In Tissue Regenerative Therapy Market ...  Digital Journal Adenoid Cystic Carcinoma Pipeline Analysis Demonstrates Novel 5 ...  Digital Journal Bridging the Gap to Reach Treatment Goals in DLBCL Advanced Therapy Medicinal Products Market ? A Comprehensive ...  Trends In Globe Global Psoriasis Drugs Market 2023: Topical Products to Account for ...  Digital Journal AAD 2023 : Incyte Presentations and Posters Multiple Sclerosis Drugs Market: The Multiple Sclerosis Drugs ...  Digital Journal Single Cell Analysis Market is expected to grow at a significant CAGR of 17.8%  EIN News Kessler Topaz Meltzer & Check, LLP Announces Pendency of Class ...  PR Newswire Cancer Drugs Market to See Massive Growth by 2029 | Johnson and ...  Digital Journal Celgene Must Face Humana Suit on 'Supracompetitive' Drug Prices  Bloomberg Law Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a ...  Business Wire Bristol Myers must face a lawsuit filed by former Celgene shareholders  FiercePharma Bristol-Myers Squibb to Acquire Celgene to Create a Premier ...  Business Wire Wellington Management Does Not Support Bristol-Myers Squibb's ...  Business Wire Natco Pharma launches additional strengths of cancer drug Revlimid  CNBCTV18 Gene Therapy Market Report (2022 to 2030) - Novartis AG, Spark ...  Yahoo Finance Celgene Corporation and Acceleron Pharma Announce U.S. FDA ...  Business Wire Sun Pharma gets U.S. FDA nod to market generic medication  The Hindu Kyn Therapeutics Enters into Global Strategic Collaboration with ...  Business Wire Patent settlement and licence agreements  Maddocks Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its ...  Business Wire Celgene Completes Acquisition of Juno Therapeutics, Inc ...  Business Wire HealthCor Offshore Master Fund LP et al v. Celgene Corporation et ...  OffshoreAlert Celgene signs deal with BeiGene for tumor cancer treatment  Reuters Editas Medicine and Celgene Corporation Amend Existing ...  GlobeNewswire Celgene (CELG) Updates on R&D Deep Dive (Multiple Myeloma ...  Seeking Alpha ACCC delivers bitter pill on patent settlement  Allens Sun Pharma settles patent litigation with Celgene Corporation for cancer drug Revlimid  Economic Times Celgene Corporation: How to Effectively Buy Into CELG Stock  Yahoo Finance Teva and Natco Announce Launch of additional strengths for the ...  Business Wire Celgene buys EngMab for $600M and will head into clinic next year  FierceBiotech BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles ...  PR Newswire Vividion Therapeutics Announces Strategic Research Collaboration ...  PR Newswire Bristol-Myers/Celgene: Win-Win Merger (NASDAQ:CELG)  Seeking Alpha Why Celgene's Beaten Down Stock Can Rise 28%  Investopedia Celgene Can't Delay Cancer Drug Antitrust Case, Court Told  Law360 Bristol Myers Squibb - LOTTE to Purchase Bristol Myers Squibb ... Celgene to pay $280 million to settle off-label marketing case  Reuters Pancreatic Cancer Treatment Market Research Update, Size ...  Digital Journal Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion Celgene, sold for $74 billion, leaves a legacy of chutzpah in science ...  STAT Celgene, Bristol-Myers set $2.2 billion termination fee for their mega ... Celgene to Acquire Delinia, Inc.  Business Wire Ankylosing Spondylitis Market Growth and Status Explored in a New Research Report 2032  openPR Generic Revlimid Could Sink Celgene (NASDAQ:CELG)  Seeking Alpha Celgene and Juno Announce Celgene Exercised Option to Develop ...  Business Wire Celgene In 2018: A Look At The Long Thesis (NASDAQ:CELG)  Seeking Alpha Is Celgene A Growth Or A Value Stock? (NASDAQ:CELG)  Seeking Alpha Skyhawk Therapeutics Announces Strategic Collaboration with ...  PR Newswire Osteogenesis Imperfecta Treatment Market Size Is Estimated To ...  Medgadget Bristol Myers Squibb - Bristol Myers Squibb Reports Fourth Quarter ... Celgene to buy Abraxis BioScience for $2.9 billion Bristol-Myers Squibb: Great Deal On Celgene And Undervalued ...  Seeking Alpha Celgene to Acquire Avila Therapeutics  Business Wire With Bristol-Myers CVR, Investors Can Bet on 3 Drugs in Celgene?s Pipeline  Barron's It had to happen: Ex-Celgene shareholders sue Bristol Myers ...  FiercePharma Celgene & Juno: The Latest in a Bumper Crop of Biotech M&A?  Barron's Celgene Stock History: The Biotech's Path to Gigantic Gains  The Motley Fool FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of ...  Business Wire 'Major blunder': Ex-staffers blast Bristol Myers Squibb's handling of ...  FiercePharma Soon-Shiong's NantCell gets $30M from Celgene - L.A. Business First  The Business Journals Celgene (CELG) Stock Will Eventually Break Out of Sideways Trend  TheStreet Olympic Swimmer and Author Dara Torres Teams Up With Celgene ...  Business Wire Acceleron Pharma Announces Global Collaboration with Celgene ...  FierceBiotech Bristol Myers Squibb - Bristol Myers Squibb Data at ASCO and EHA ... Bristol-Myers: Fattening Up The Pipeline With Celgene (NYSE:BMY)  Seeking Alpha Dragonfly Therapeutics Announces Strategic Collaboration with ...  PR Newswire Should You Own Celgene In 2017? Part 7 (NASDAQ:CELG)  Seeking Alpha Starboard abandons campaign to scuttle Bristol-Myers-Celgene deal  Reuters Better Buy: Geron vs. Celgene  The Motley Fool Antengene Corporation Appoints Former Celgene ANZ General ...  PR Newswire Celgene takes its most aggressive price hikes yet on Revlimid ...  FiercePharma Celgene bags a build-to-buy biotech in $485M cancer deal  FierceBiotech Seven Habits Of Celgene's Highly Successful Strategy  Forbes Gene Therapy Market Size, Growth, Trends, Report 2022-2028  openPR Bristol-Myers Squibb defends Celgene takeover as 'best path'  Financial Times FACIT and Triphase Accelerator Announce New Partnership with ...  GlobeNewswire Celgene Appoints Tuomo Pätsi as President of EMEA and Commits ...  Business Wire Should You Own Celgene In 2017? Part 6 (NASDAQ:CELG)  Seeking Alpha Patent Infringement Suit Against Bristol-Myers, Celgene Targets ... Former Celgene, Portola Lawyers Land New Big Pharma Roles  Bloomberg Law A 7-year-old alliance between Celgene and Acceleron is paying off ...  Endpoints News Regenacy Pharmaceuticals to be Launched by Acetylon ...  Business Wire Deal of the Year: Bristol-Myers Squibb buys Celgene  BioPharma Dive Editas Expands Its Celgene Partnership After Another Strong Quarter  The Motley Fool Celgene COO Scott Smith exits suddenly in wake of MS fumble ...  FiercePharma BMS reveals its post-Celgene takeover management team  pharmaphorum FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for ...  Business Wire Why It's Time That Markets Assign More Value To Celgene's Drug ...  Seeking Alpha Should You Own Celgene In 2017? Part 2 (NASDAQ:CELG)  Seeking Alpha Celgene pays high upfront to extend deal with Forma  BioPharma Dive Bad year at Celgene? Forget about it. CEO Mark Alles nabbed a big ...  Endpoints News Celgene Stock Split: Is the Biotech Ready to Split Again?  The Motley Fool Prothena Announces Global Neuroscience Research ...  GlobeNewswire

Search the Internet:

Website Width:
Bookmark and Share

 Background image:

Copyright@2010-2023 -, all rights reserved.
Investment Forum Stock Quotes Investment News Investment Chat Disclaimer Webmaster Resources